艾司西酞普兰联合认知训练对抑郁症患者的有效性与安全性

Efficacy and safety of escitalopram combined with cognitive training in patients with depression

目的探讨抑郁症患者选用艾司西酞普兰联合认知行为治疗的效果。方法遴选92例抑郁症患者(2019年1月~2020年6月)按1∶1比例(随机数字表法)分为对照组(n=46)和观察组(n=46);选对照组选用艾司西酞普兰治疗,观察组在对照组基础上加用认知训练,统计两组临床疗效,不良反应评分,复发率,临床指标。结果(1)临床疗效:观察组有效率为95.65%高于对照组的78.26%(P<0.05);(2)复发率:观察组(三个月4.35%,6个月8.69%)低于对照组(P<0.05);(3)不良反应评分:观察组第1周与对照组相比无差异P>0.05;第6周(4.31±1.06)分低于对照组(7.42±0.52)分(P<0.05);(4)临床指标:观察组抑郁状态,焦虑状态,S100B低于对照组,社会功能,认知功能,脑源性神经营养因子(BDNF)高于对照组(P<0.05)。结论艾司西酞普兰联合认知行为在抑郁症治疗中效果确切,可改善其抑郁状态及认知功能,亦可促进其社会功能恢复,且安全性好。

Objective To explore the value of the combination of esmcitalopram and cognitive behavior in depression patients.Methods 92 patients with depression were selected from January 2019 to December 2020 control group(n=46,esmcitalopram)and observation group(n=46,cognitive behavior therapy based on the control group).The clinical efficacy,adverse response score,recurrence rate and clinical indicators were statistically analyzed.Results(1)The clinical effect:the observation group(95.65%)was higher than the control group(78.26%)(P<0.05).(2)Recurrence rate:the recurrence rate of observation group(4.35%in 3 months and 8.69%in 6 months)was lower than that of the control group(P<0.05).(3)Adverse reactions score:there was no difference between the observation group and the control group in the first week(P>0.05),the score in the sixth week(4.31±1.06)was lower than that of the control group(7.42±0.52)(P<0.05).(4)Clinical indicators:the depression,anxiety and S100B in the observation group were lower than that of the control group,and the social function,cognitive function and BDNF were higher than that of the control group(P<0.05).Conclusion The effect of esmcitalopram combined with cognitive behavior in depression treatment is accurate,it can improve the depression state and cognitive function,promote the recovery of social function with high safety.